These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29717168)

  • 41. Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.
    Merk D; Lamers C; Ahmad K; Carrasco Gomez R; Schneider G; Steinhilber D; Schubert-Zsilavecz M
    J Med Chem; 2014 Oct; 57(19):8035-55. PubMed ID: 25255039
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression.
    Claudel T; Inoue Y; Barbier O; Duran-Sandoval D; Kosykh V; Fruchart J; Fruchart JC; Gonzalez FJ; Staels B
    Gastroenterology; 2003 Aug; 125(2):544-55. PubMed ID: 12891557
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
    Ho PP; Steinman L
    Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1.
    Alvarez L; Jara P; Sánchez-Sabaté E; Hierro L; Larrauri J; Díaz MC; Camarena C; De la Vega A; Frauca E; López-Collazo E; Lapunzina P
    Hum Mol Genet; 2004 Oct; 13(20):2451-60. PubMed ID: 15317749
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regulation of human liver delta-aminolevulinic acid synthase by bile acids.
    Peyer AK; Jung D; Beer M; Gnerre C; Keogh A; Stroka D; Zavolan M; Meyer UA
    Hepatology; 2007 Dec; 46(6):1960-70. PubMed ID: 17975826
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alisol B 23-acetate protects against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated regulation of transporters and enzymes involved in bile acid homeostasis.
    Meng Q; Chen XL; Wang CY; Liu Q; Sun HJ; Sun PY; Huo XK; Liu ZH; Yao JH; Liu KX
    Toxicol Appl Pharmacol; 2015 Mar; 283(3):178-86. PubMed ID: 25655198
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structure-activity relationship of bile alcohols as human farnesoid X receptor agonist.
    Iguchi Y; Kihira K; Nishimaki-Mogami T; Une M
    Steroids; 2010 Jan; 75(1):95-100. PubMed ID: 19913569
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis.
    Mencarelli A; Renga B; Migliorati M; Cipriani S; Distrutti E; Santucci L; Fiorucci S
    J Immunol; 2009 Nov; 183(10):6657-66. PubMed ID: 19880446
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Functional analysis of the rat bile salt export pump gene promoter.
    Gerloff T; Geier A; Roots I; Meier PJ; Gartung C
    Eur J Biochem; 2002 Jul; 269(14):3495-503. PubMed ID: 12135489
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Polyunsaturated fatty acids are FXR ligands and differentially regulate expression of FXR targets.
    Zhao A; Yu J; Lew JL; Huang L; Wright SD; Cui J
    DNA Cell Biol; 2004 Aug; 23(8):519-26. PubMed ID: 15307955
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The glucocorticoid mometasone furoate is a novel FXR ligand that decreases inflammatory but not metabolic gene expression.
    Bijsmans IT; Guercini C; Ramos Pittol JM; Omta W; Milona A; Lelieveld D; Egan DA; Pellicciari R; Gioiello A; van Mil SW
    Sci Rep; 2015 Sep; 5():14086. PubMed ID: 26369990
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FXR, a target for different diseases.
    Wang YD; Chen WD; Huang W
    Histol Histopathol; 2008 May; 23(5):621-7. PubMed ID: 18283647
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis.
    Schumacher JD; Guo GL
    Handb Exp Pharmacol; 2019; 256():325-357. PubMed ID: 31201553
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands.
    Finamore C; Festa C; Renga B; Sepe V; Carino A; Masullo D; Biagioli M; Marchianò S; Capolupo A; Monti MC; Fiorucci S; Zampella A
    Sci Rep; 2016 Jul; 6():29320. PubMed ID: 27381677
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Beyond bile acids: targeting Farnesoid X Receptor (FXR) with natural and synthetic ligands.
    Carotti A; Marinozzi M; Custodi C; Cerra B; Pellicciari R; Gioiello A; Macchiarulo A
    Curr Top Med Chem; 2014; 14(19):2129-42. PubMed ID: 25388537
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of bile acids and bile acid receptors in metabolic regulation.
    Lefebvre P; Cariou B; Lien F; Kuipers F; Staels B
    Physiol Rev; 2009 Jan; 89(1):147-91. PubMed ID: 19126757
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk.
    Norona LM; Fullerton A; Lawson C; Leung L; Brumm J; Kiyota T; Maher J; Khojasteh C; Proctor WR
    Arch Toxicol; 2020 Sep; 94(9):3185-3200. PubMed ID: 32583097
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.
    Flesch D; Gabler M; Lill A; Gomez RC; Steri R; Schneider G; Stark H; Schubert-Zsilavecz M; Merk D
    Bioorg Med Chem; 2015 Jul; 23(13):3490-8. PubMed ID: 25934227
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Farnesoid X receptor modulators 2014-present: a patent review.
    Sepe V; Distrutti E; Fiorucci S; Zampella A
    Expert Opin Ther Pat; 2018 May; 28(5):351-364. PubMed ID: 29649907
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regulation of the human bile acid UDP-glucuronosyltransferase 1A3 by the farnesoid X receptor and bile acids.
    Erichsen TJ; Aehlen A; Ehmer U; Kalthoff S; Manns MP; Strassburg CP
    J Hepatol; 2010 Apr; 52(4):570-8. PubMed ID: 20189675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.